教育经历 2001.09—2005.07山东大学生物化学与分子生物学专业本科生 2005.09—2010.07中国科学院研究生院生物化学与分子生物学专业博士研究生 工作经历 2011.01—2015.06美国哈佛大学Dana-Farber 癌症研究所博士后 2015.07—2016.05美国哈佛大学Dana-Farber 癌症研究所讲师（junior faculty） 2016.10— 2021.07复旦大学药学院，博士生导师 2017.01— 至今复旦大学附属闵行医院兼职教授 2021.08— 至今复旦大学基础医学院，博士生导师 获得奖项 2019年，增爱·长木学术奖，增爱中国基金会 2010年 欧洲生物化学学会联盟, FEBS Youth Travel Fellowship

靶向BCL9/β-catenin的药理学机制研究 肿瘤免疫治疗新药开发

2017-今 中国药理学会 会员 2018-今 上海市药理学会 会员 2019-今 中国老年学和老年医学学会老年肿瘤分会专家委员会 专业委员 2021-今 中国药理学会化药专业委员会 专业委员 2022-今 中国抗癌协会 会员

Hu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z., He, Y., Zhu, Y., Huang, C., Yang, X., Shi, Y., Qiu, S., Sun, H., Zhu, A., Zhou, J., Xu, Y., Zhu, D.*, Fan, J.* Interferon-α potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov., 2022. DOI: 10.1158/2159-8290.CD-21-1022 (IF: 39.4) Xia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., Xie, D., Zhu, D.* RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers. J Exp Clin Canc Res. 2022. DOI : 10.1186/s13046-022-02289-2 (IF: 11.1) Feng, M., Wu, Z., Zhou, Y., Wei, Z., Tian, E., Mei, S., Zhu, Y., Liu, C., He, F., Li, H., Xie, C., Jin, J., Dong, J., Yang, D., Yu, K., Qian, J., Lambrechts, D.*, Wang, M.*, Zhu, D.* BCL9 regulates CD226 and CD96 checkpoints in CD8+ T c ells to improve PD-1 response in cancer. Signal Transduct Target Ther, 2021, 6, 313. (5 year IF: 22.1) Wang, X., Feng, M., Xiao, T., Guo, B., Liu, D., Liu, C., Pei, J., Liu, Q., Xiao, Y., Rosin-Arbesfeld, R., Shi, Y., Zhou, Y., Yang, M., Feng, Y., Jiang, Y., Shao, Z., Yu, K.*, Zhu, D.* BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. Oncogene, 2021, 40: 2982- 2997. (IF: 9.8) Liu, C., Zhou, F., Yan, Z., Shen, L., Zhang, X., He, F., Wang, H., Lu, X., Yu, K., Zhao, Y.*, Zhu, D.* Discovery of a novel, potent, and selective small-molecu le inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumor efficacy. Br. J. Pharmacol., 2021, 178(13): 2651-2670. (IF: 8.7) Tian, E., Yu, M., Feng, M., Wang, Y., Xie, Q.*, Zhu, D.* RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer. Pharmacol.Res., 2021, 172:105793. (IF: 7. 6) Feng, M., Zhao, Z., Yang, M., Ji, J., Zhu, D.*, T-cell-based immunotherapy in colorectal cancer. Cancer Lett., 2021, 498(40): 201-209. (IF., 8.6) Feng, M., Jin, J., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Raf, S., Zhu, A., Feng, Y.*, Zhu, D.* Pharmacolo gical inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockad es by modulating Treg cells. Sci. Adv., 2019, 5(5): 1-16. (IF: 14.1) Zhu, D., Wang, Z., Zhao, J., Calimeri, T., Meng, J., Hideshima, T., Fulciniti, M., Kang, Y., Ficarro, S., Tai, Y., Hunter, Z., McMilin, D., Tong, H., Mitsiades, C., Wu, C., Treon, S., Dorfman, D., Pinkus, G., Munshi, N., Tassone, P., Marto, J., Anderson, K., Carrasco, R.* The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med., 2015, 21(6): 572-580. (IF: 53.4) Takada, K.#, Zhu, D.#, Bird, GH. #, Sukhdeol, K., Zhao, J., Mani, M., Lemieux, M., Carrasco, D., Ryan, J., Horst, D., Fulciniti, M., Mushi, NC., Xu, W., Kung, AL., Shivdasani, R., Walensky, L.*, Carrasco, R.* Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling. Sci Transl Med., 2012, 4(148): 1-13. (IF: 17.9 )